These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 25057438)

  • 1. Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?
    Safarpour D; Pakneshan S; Tavassoli FA
    Am J Cancer Res; 2014; 4(4):353-68. PubMed ID: 25057438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen Receptor Expression in ER and PR Negative Breast Cancer-A Study from a Tertiary Hospital in Northern India.
    Sidhu S; Kwatra KS; Kinsley PA
    South Asian J Cancer; 2023 Oct; 12(4):319-325. PubMed ID: 38130277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterizing Breast Cancer in a Population with Increased Prevalence of Triple-Negative Breast Cancer: Androgen Receptor and ALDH1 Expression in Ghanaian Women.
    Proctor E; Kidwell KM; Jiagge E; Bensenhaver J; Awuah B; Gyan K; Toy K; Oppong JK; Kyei I; Aitpillah F; Osei-Bonsu E; Adjei E; Ohene-Yeboah M; Brewer RN; Fondjo LA; Owusu-Afriyie O; Wicha M; Merajver S; Kleer C; Newman L
    Ann Surg Oncol; 2015 Nov; 22(12):3831-5. PubMed ID: 25743329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients.
    Qi JP; Yang YL; Zhu H; Wang J; Jia Y; Liu N; Song YJ; Zan LK; Zhang X; Zhou M; Gu YH; Liu T; Hicks DG; Tang P
    Breast Cancer (Auckl); 2012; 6():1-8. PubMed ID: 22259247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A SOX10+/AR- immunoprofile may identify a subset of low positive ER carcinomas with a wider range of ER expression.
    Keske A; Shetty S; Weisman P; Yu Q; McGregor SM; Xu J
    Pathol Res Pract; 2023 Aug; 248():154628. PubMed ID: 37399589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
    Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
    J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRPS1 and GATA3 Expression in Invasive Breast Carcinoma With Apocrine Differentiation.
    Wang J; Peng Y; Sun H; Aung PP; Resetkova E; Yam C; Sahin AA; Huo L; Ding Q
    Arch Pathol Lab Med; 2024 Feb; 148(2):200-205. PubMed ID: 37074839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers.
    Micello D; Marando A; Sahnane N; Riva C; Capella C; Sessa F
    Virchows Arch; 2010 Oct; 457(4):467-76. PubMed ID: 20809337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A targetable androgen receptor-positive breast cancer subtype hidden among the triple-negative cancers.
    Safarpour D; Tavassoli FA
    Arch Pathol Lab Med; 2015 May; 139(5):612-7. PubMed ID: 25310144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pure Apocrine Carcinomas Represent a Clinicopathologically Distinct Androgen Receptor-Positive Subset of Triple-Negative Breast Cancers.
    Mills AM; E Gottlieb C; M Wendroth S; M Brenin C; Atkins KA
    Am J Surg Pathol; 2016 Aug; 40(8):1109-16. PubMed ID: 27259012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers.
    Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW; Lee KS
    Ann Oncol; 2011 Aug; 22(8):1755-62. PubMed ID: 21310761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer.
    Christenson JL; O'Neill KI; Williams MM; Spoelstra NS; Jones KL; Trahan GD; Reese J; Van Patten ET; Elias A; Eisner JR; Richer JK
    Mol Cancer Ther; 2021 Jun; 20(6):1062-1071. PubMed ID: 33722849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor expression and its relationship with clinicopathological parameters in an Iranian population with invasive breast carcinoma.
    Mohammadizadeh F; Sajadieh S; Sajjadieh H; Kasaei Z
    Adv Biomed Res; 2014; 3():132. PubMed ID: 24949303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quadruple Negative Breast Cancers (QNBC) Demonstrate Subtype Consistency among Primary and Recurrent or Metastatic Breast Cancer.
    Angajala A; Mothershed E; Davis MB; Tripathi S; He Q; Bedi D; Dean-Colomb W; Yates C
    Transl Oncol; 2019 Mar; 12(3):493-501. PubMed ID: 30594038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
    Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
    Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NKX3.1 is expressed in ER-positive and AR-positive primary breast carcinomas.
    Asch-Kendrick RJ; Samols MA; Lilo MT; Subhawong AP; Sharma R; Illei PB; Argani P; Cimino-Mathews A
    J Clin Pathol; 2014 Sep; 67(9):768-71. PubMed ID: 24996432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of androgen receptor expression and molecular alterations in metastatic triple-negative or low hormone receptor breast carcinomas.
    Shen T; Wei L; Li X; Parwani AV; Li Z
    Hum Pathol; 2021 Oct; 116():73-81. PubMed ID: 34310983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.